A Study about Blood Pressure Management in Patients with Primary Aldosteronism
Official Title
A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Effectiveness of CIN-107 for the Management of Blood Pressure in Patients with Primary Aldosteronism
Purpose
The purpose of this study is to see how the study drug CIN-107 works in managing blood pressure in patients with primary aldosteronism (PA), a hormone disorder which causes your body to produce too much of the hormone aldosterone.
The duration of this study is 74 weeks.
Could this study be right for you?
- Diagnosis of primary aldosteronism (PA)
- Taking an MRA to control BP, such as Spironolactone or Eplerenone, or not yet taking an MRA
Age Range
18 and up
Evaluating a Cell-Based Therapy in New Living Donor Kidney Transplant Recipients and Donors
Official Title
FREEDOM 1, A randomized, controlled, multi-center, safety and efficacy study of FCR001 cell-based therapy relative to a tacrolimus and mycophenolate-based regimen in de novo living donor renal transplant recipients, and safety in FCR001 donors
Purpose
The purpose of this study is to learn more about whether FCR001, an investigational cell therapy, can prevent the rejection of living donor kidney transplants without the need for lifelong anti-rejection drugs.
Could this study be right for you?
• Recipient age ≥ 18 years
• Donor age ≥ 18 and ≤ 60 years
• Recipient of a first kidney transplant from a living donor
• Not diagnosed with or treated for any type of cancer (donor or recipient)
Age Range
18 and up